SEARCH

SEARCH BY CITATION

References

  • Al-Yaman F, Genton B, Mokela D et al. (1996) Resistance of Plasmodium falciparum malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990–1993. Papua New Guinea Medical Journal 39, 1622.
  • Al-Yaman F, Genton B, Reeder JC, Anders RF & Alpers MP (1997) Evidence that recurrent Plasmodium falciparum infection is caused by recrudescence of resistant parasites. American Journal of Tropical Medicine and Hygiene 56, 436439.
  • Anderson SL, Berman J, Kuschner R et al. (1995) Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Annals of Internal Medicine 123, 771773.
  • Attlmayr B, Kollaritsch H, Wernsdorfer WH et al. (2005) Drug sensitivity of Plasmodium falciparum along the Thai-Myanmar border using the new field-deployable HRP2 in vitro assay. Wiener Klinische Wochenschrift 117(Suppl. 4), 3538.
  • Attlmayr B, Thriemer K, Haque R et al. (2006) In vitro antimalarial drug resistance in Southeastern Bangladesh. Wiener Klinische Wochenschrift 118, 5861.
  • Bablok W, Passing H, Bender R & Schneider B (1988) A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. Journal of Clinical Chemistry and Clinical Biochemistry 26, 783790.
  • Basco LK & Ringwald P (2003) In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrobial Agents and Chemotherapy 47, 13911394.
  • Basco LK, Bickii J & Ringwald P (1998) In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Antimicrobial Agents and Chemotherapy 42, 23472351.
  • Basco LK, Ndounga M, Keundjian A & Ringwald P (2002) Molecular epidemiology of malaria in cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children. American Journal of Tropical Medicine and Hygiene 66, 117123.
  • Bland JM & Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307310.
  • Brasseur P, Guigemde R, Diallo S et al. (1999) Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 93, 645650.
  • Brockman A, Singlam S, Phiaphun L et al. (2004) Field evaluation of a novel colorimetric method – double-site enzyme-linked lactate dehydrogenase immunodetection assay to determine drug susceptibilities of Plasmodium falciparum clinical isolates from northwestern Thailand. Antimicrobial Agents and Chemotherapy 48, 14261429.
  • Carnevale EP, Kouri D, DaRe JT et al. (2007) A multiplex ligase detection reaction-fluorescent microsphere assay for simultaneous detection of single nucleotide polymorphisms associated with Plasmodium falciparum drug resistance. Journal of Clinical Microbiology 45, 752761.
  • Casey GJ, Ginny M, Uranoli M et al. (2004) Molecular analysis of Plasmodium falciparum from drug treatment failure patients in Papua New Guinea. American Journal of Tropical Medicine and Hygiene 70, 251255.
  • Cattani JA, Tulloch JL, Vrbova H et al. (1986) The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. American Journal of Tropical Medicine and Hygiene 35, 315.
  • Chulay JD, Haynes JD, Diggs CL (1983) P. falciparum: assessment of in vitro growth by [3H]-hypoxanthine incorporation. Experimental Parasitology 55, 138146.
  • Cremer G, Basco LK, Le Bras J, Camus D & Slomianny C (1995) Plasmodium falciparum: detection of P-glycoprotein in chloroquine-susceptible and chloroquine-resistant clones and isolates. Experimental Parasitology 81, 18.
  • Darlow B & Vrbova H (1981) Chloroquine-resistant Plasmodium falciparum malaria in Madang children. Papua New Guinea Medical Journal 24, 9698.
  • Deloron P, Le Bras J, Ramanamirija JA & Coulanges P (1985) Plasmodium falciparum in Madagascar: in vivo and in vitro sensitivity to seven drugs. Annals of Tropical Medicine and Parasitology 79, 357365.
  • Dorn A, Vippagunta SR, Matile H et al. (1998) An assessment of drug-haematin as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochemical Pharmacology 55, 727736.
  • Dulay IS, Gibson FD, Eyeson-Annan MB & Narara A (1987) Chloroquine resistance in Plasmodium falciparum and its geographical distribution in Papua New Guinea. Papua New Guinea Medical Journal 30, 281290.
  • Ekland EH & Fidock DA (2008) In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. International Journal for Parasitology 38, 743747.
  • Fan B, Zhao W, Ma XW et al. (1998) In vitro sensitivity of Plasmodium falciparum to chloroquine, piperaquine, pyronaridine and artesunate in Yuxi prefecture of Yunnan province. Chinese Journal of Parasitology and Parasitic Diseases 16, 460462.
  • Genton B, Baea K, Lorry K et al. (2005) Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. Papua New Guinea Medical Journal 48, 141150.
  • Grimmond TR, Donovan KO & Riley ID (1976) Chloroquine resistant malaria in Papua New Guinea. Papua New Guinea Medical Journal 19, 184185.
  • Han CM (1978) Studies on the occurrence of a strain of chloroquine-resistant Plasmodium falciparum in Papua New Guinea. Papua New Guinea Medical Journal 21, 306316.
  • Hodel EM, Marfurt J, Muller D et al. (2008) Lack of multiple copies of pfmdr1 gene in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene 102, 11511153.
  • Hombhanje FW (1998) In vitro susceptibility of Plasmodium falciparum to four antimalarial drugs in the Central Province of Papua New Guinea. Papua New Guinea Medical Journal 41, 5158.
  • Johnson DJ, Fidock DA, Mungthin M et al. (2004) Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Molecular Cell 15, 867877.
  • Kaddouri H, Nakache S, Houze S, Mentre F & Le Bras J (2006) Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrobial Agents and Chemotherapy 50, 33433349.
  • Karunajeewa HA, Mueller I, Senn M et al. (2008) A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 359, 25452557.
  • Le Bras J & Ringwald P (1990) Plasmodium falciparum chemoresistance. The situation in Africa in 1989. Medecine Tropicale 50, 161162.
  • Lin SG, Liu DQ, Zhuo KR et al. (2005) Determination of sensitivity of Plasmodium falciparum to antimalarials in Ledong County, Hainan Province. China Tropical Medicine 5, 17071708.
  • Makler MT & Hinrichs DJ (1993) Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. American Journal of Tropical Medicine and Hygiene 48, 205210.
  • Makler MT, Ries JM, Williams JA et al. (1993) Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. American Journal of Tropical Medicine and Hygiene 48, 739741.
  • Marfurt J, Mueller I, Sie A et al. (2007) Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. American Journal of Tropical Medicine and Hygiene 77, 947954.
  • Mayxay M, Barends M, Brockman A et al. (2007) In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos). American Journal of Tropical Medicine and Hygiene 76, 245250.
  • Mehlotra RK, Mattera G, Bhatia K et al. (2005) Insight into the early spread of chloroquine-resistant Plasmodium falciparum infections in Papua New Guinea. Journal of Infectious Diseases 192, 21742179.
  • Mita T, Tanabe K, Takahashi N et al. (2007) Independent evolution of pyrimethamine resistance in Plasmodium falciparum isolates in Melanesia. Antimicrobial Agents and Chemotherapy 51, 10711077.
  • Mueller I, Bockarie M, Alpers M & Smith T (2003) The epidemiology of malaria in Papua New Guinea. Trends in Parasitology 19, 253259.
  • Nkhoma S, Molyneux M & Ward S (2007) In vitro antimalarial susceptibility profile and prcrt/pfmdr-1 genotypes of Plasmodium falciparum field isolates from Malawi. American Journal of Tropical Medicine and Hygiene 76, 11071112.
  • Noedl H (2002) HN-NonLin V1.1. Armed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
  • Noedl H, Wernsdorfer WH, Krudsood S et al. (2001) Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailand. Acta Tropica 80, 3944.
  • Noedl H, Krudsood S, Chalermratana K et al. (2006) Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clinical Infectious Diseases 43, 12641271.
  • Noedl H, Krudsood S, Leowattana W et al. (2007) In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrobial Agents and Chemotherapy 51, 651656.
  • Noedl H, Se Y, Schaecher K et al. (2008) Evidence of artemisinin-resistant malaria in western Cambodia. New England Journal of Medicine 359, 26192620.
  • Oduro AR, Anyorigia T, Hodgson A et al. (2005) A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. Tropical Medicine and International Health 10, 179184.
  • Papua New Guinea Department of Health (2000) Standard Treatment of Common Illnesses of Children in Papua New Guinea. Government of Papua New Guinea, Madang.
  • Peel SA, Bright P, Yount B, Handy J & Baric RS (1994) A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. American Journal of Tropical Medicine and Hygiene 51, 648658.
  • Pradines B, Tall A, Parzy D et al. (1998) In vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. Journal of Antimicrobial Chemotherapy 42, 333339.
  • Pradines B, Hovette P, Fusai T et al. (2006) Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. Journal of Clinical Microbiology 44, 24042408.
  • Price RN, Uhlemann AC, Brockman A et al. (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438447.
  • Ringwald P, Bickii J & Basco LK (1996) In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. American Journal of Tropical Medicine and Hygiene 55, 254258.
  • Saint-Yves IF (1971) The alleged resistance of Plasmodium falciparum to chloroquine in the Milne Bay District. Papua New Guinea Medical Journal 14, 7778.
  • Saito-Nakano Y, Tanabe K, Kamei K et al. (2008) Genetic evidence for Plasmodium falciparum resistance to chloroquine and pyrimethamine in Indochina and the Western Pacific between 1984 and 1998. American Journal of Tropical Medicine and Hygiene 79, 613619.
  • Sapak P, Garner P, Baea M et al. (1991) Ineffectiveness of amodiaquine against Plasmodium falciparum malaria in symptomatic young children living in an endemic malarious area of Papua New Guinea. Journal of Tropical Pediatrics 37, 185190.
  • Schuurkamp GJT & Kereu RK (1989) Resistance of Plasmodium falciparum to chemotherapy with 4-aminoquinolines in the Ok Tedi area of Papua New Guinea. Papua New Guinea Medical Journal 32, 3344.
  • Sidhu AB, Verdier-Pinard D & Fidock DA (2002) Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298, 210213.
  • Sidhu AB, Valderramos SG & Fidock DA (2005) Pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Molecular Microbiology 57, 913926.
  • Sidhu AB, Uhlemann AC, Valderramos SG et al. (2006) Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. Journal of Infectious Diseases 194, 528535.
  • Slater AFG & Cerami A (1992) Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 355, 167169.
  • Trager W & Jensen JB (1976) Human malaria parasites in continuous culture. Science 193, 673675.
  • Trenholme KR, Kum DE, Raiko AK et al. (1993) Resistance of Plasmodium falciparum to amodiaquine in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene 87, 464466.
  • WernsdorferWH & McGregorWH (eds) (1988) Malaria: Principles and Practice of Malariology. Edinburgh, Churchchill Livingstone.
  • World Health Organization (2005) Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996–2004. WHO/HTM/MAL/2005.1103.
  • World Health Organization (2006) Guidelines for the Treatment of Malaria. WHO, Geneva.
  • Yang H, Gao B & Huang K (1999a) Comparison of naphthoquine, metronidazole and norfloxacine to artesunate sensitive and resistant P. falciparum strains. Practical Parasitic Diseases 2. Available at: http://www.labmed.cn/Article/jshch/200508/1421.html.
  • Yang H, Liu D, Huang K et al. (1999b) Assay of sensitivity of Plasmodium falciparum to chloroquine, amodiaquine, piperaquine, mefloquine and quinine in Yunnan province. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 17, 4345.
  • Yung AP & Bennett NM (1976) Chloroquine-resistant falciparum malaria acquired in Papua New Guinea. Medical Journal of Australia 2, 845.